US 12,343,376 B2
Methods for inhibiting diazepam binding protein
Guido Kroemer, Paris (FR); and José Manuel Bravo San Pedro, Paris (FR)
Assigned to INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE, Paris (FR); ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP), Paris (FR); UNIVERSITÉ PARIS CITÉ, Paris (FR); and SORBONNE UNIVERSITÉ, Paris (FR)
Filed by INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE, Paris (FR); ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP), Paris (FR); UNIVERSITÉ PARIS CITÉ, Paris (FR); and SORBONNE UNIVERSITÉ, Paris (FR)
Filed on Feb. 16, 2024, as Appl. No. 18/444,102.
Application 18/444,102 is a continuation of application No. 17/935,261, filed on Sep. 26, 2022, granted, now 11,905,330.
Application 17/935,261 is a continuation of application No. 16/648,744, previously published as PCT/EP2018/075286, filed on Sep. 19, 2018.
Claims priority of application No. 173062293 (EP), filed on Sep. 20, 2017.
Prior Publication US 2024/0245750 A1, Jul. 25, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/395 (2006.01); A61K 38/17 (2006.01); A61K 39/00 (2006.01); A61K 39/39 (2006.01); A61P 3/04 (2006.01); C07K 16/18 (2006.01); C07K 16/28 (2006.01); G01N 33/68 (2006.01)
CPC A61K 38/17 (2013.01) [A61K 39/0005 (2013.01); A61K 39/39 (2013.01); A61P 3/04 (2018.01); C07K 16/18 (2013.01); C07K 16/286 (2013.01); G01N 33/68 (2013.01); A61K 2039/505 (2013.01); A61K 2039/545 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01)] 17 Claims
 
1. A method comprising contacting a tissue of a patient with an antibody that binds human extracellular diazepam binding inhibitor (DBI) at a dosage sufficient to reduce the activity of human extracellular DBI in the patient, as determined in an in vitro assay performed on a sample obtained from the patient, wherein the patient suffers from metabolic syndrome.